blinatumomab (Blincyto)

following a full submission assessed under the end of life and ultra orphan processes

blinatumomab (Blincyto®) is accepted for use within NHS Scotland.

Indication under review: The treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).

In a non-comparative phase II study of patients with relapsed or refractory Philadelphia chromosome-negative B-precursor ALL, blinatumomab was associated with clinically relevant complete remission rates. Controlled data with clinical outcomes are currently lacking.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of blinatumomab. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.